Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 735-744

  Brockstein, Bruce ^a   Haraf, Daniel J ^a   Stenson, Kerstin ^a   Fasanmade, Adedigbo ^a   Stupp, Roger ^a   Glisson, Bonnie ^a   Lippman, Scott M ^a   Ratain, Mark J ^a   Sulzen, Laura ^a   Klepsch, Amy ^a   Weichselbaum, Ralph R ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DERMATITIS; DIARRHEA; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOSENSITIVITY; TREATMENT OUTCOME;

EID: 0031943762     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.735     Document Type: Article

References (25)

1. Wingo PA, Tong T, Bolden S: Cancer statistics 1995. CA 45:8-30, 1995
2. Vokes EE, Weichselbaum RR, Lippman S, et al: Head and neck cancer. N Engl J Med;328:184-190, 1993
3. Rapoport Y, Kretler S, Chaitchik S, et al: Psychosocial problems in head and neck cancer patients and their change with time since diagnosis. Ann Oncol 4:69-73, 1993
4. Brockstein B, Vokes EE: Chemoradiotherapy for head and neck cancer. PPO Updates 10:1-19, 1996
5. Munro A: An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83-91, 1995
6. El-Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838-847, 1996
7. Al-Sarraf M Le Blanc M, Giri PGS, et al: Superiority of chemoradiotherapy (CT-RT) vs. radiotherapy (RT) in patients (PTS) with locally advanced nasopharyngeal cancer (NPC): Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. Proc Am Soc Clin Oncol 15:313, 1996 (abstr 882)
8. Vokes EE, Panje WR, Schilsky RL, et al: Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: Aphase I-II study. J Clin Oncol 7:761-768, 1989
9. Haraf DJ, Vokes EE, Panje WR, et al: Survival and analysis failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor-prognosis head and neck cancer. Am J Clin Oncol 14:419-426, 1991
10. Vokes EE, Haraf DJ, McEvilly JM, et al: Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach. Ann Oncol 3:79-81, 1992
11. Kies MS, Haraf DJ, Mittal B, et al: A phase II trial of induction cisplatin, 5FU, leucovorin and interferon alpha-2B (PFL-alpha) followed by concurrent hydrea-5FU and radiation for stage IV squamous cell cancers of the head and neck (HNC). Fourth International Congress on Anticancer chemotherapy. Paris, France, 1993, p 66 (abstr)
12. Arekapudi A, Haraf D, Mittal B, et al: Concomitant radiotherapy (XRT) and chemotherapy (FHX) with 5-fluorouracil (5-FU) and hydroxyurea (HU) for organ preservation in stage II and III squamous cell head and neck cancer (SCHNC): Preliminary results of an ongoing trial. Fourth International Conference on Head and Neck Cancer, Paris, France, p 118, 1996
13. Vokes EE, Panje WR, Mick R, et al: A randomized study comparing 2 regimens of neoadjuvant and adjuvant chemotherapy in multimodal treatment for locally advanced head and neck cancer. Cancer 66:206-213, 1990
14. Vokes EE, Haraf DJ, Mick R, et al: Intensified concomitant chemoradiotherapy with and without filgrastim for poor prognosis head and neck cancer. J Clin Oncol 12:2351-2359, 1994
15. Kies MS, Haraf DJ, Mittal B, et al: Intense combined therapy with CDDP, 5-FU, hydroxyurea, and BID radiotherapy (C-FHX) for stage IV squamous cell cancer (SCC) of the head and neck. Proc Am Soc Clin Oncol 15:314, 1996 (abstr 886)
16. Haraf DJ, Weichselbaum RR, Vokes EE, et al: Reirradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease. Ann Oncol 7:913-918, 1996
17. Forastiere AA, Neuberg D, Taylor SG IV, et al: Phase II evaluation of Taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group trial. Monogr NCI 15:181-184, 1993
18. Smith RE, Thornton DE, Allen J: A phase II trial of paclitaxel in squamous cell cancer of the head and neck with correlative studies. Semin Oncol 22:41-46, 1995 (suppl 6)
19. Liebmann J, Cook JA, Fisher J, et al: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446, 1994
20. Geard CR, Jones JM, Schiff PB: Taxol and radiation. Monogr NCI 15:89-94, 1993
21. Choy H, Rodriguez FF, Koester S, et al: Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993 (suppl 11)
22. Schantz SP, Harrison LB, Hong WK, et al: Cancer of the head and neck, in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 574-672
23. Leyvraz S, Pasche P, Bauer J, et al: Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: Four year results of a phase I/II study. J Clin Oncol 12:1876-1885 , 1994
24. Taylor IV SG, Murthy AK, Caldarelli DD, et al: Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer. J Clin Oncol 7:846-854, 1989
25. Adelstein DJ, Kalish LA, Adams GL, et al: Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 11:2136-2142, 1993